Frontiers in Immunology (Feb 2023)

Development of a Syrian hamster anti-PD-L1 monoclonal antibody enables oncolytic adenoviral immunotherapy modelling in an immunocompetent virus replication permissive setting

  • James H. A. Clubb,
  • James H. A. Clubb,
  • James H. A. Clubb,
  • Tatiana V. Kudling,
  • Tatiana V. Kudling,
  • Mykhailo Girych,
  • Lyna Haybout,
  • Lyna Haybout,
  • Santeri Pakola,
  • Santeri Pakola,
  • Firas Hamdan,
  • Firas Hamdan,
  • Víctor Cervera-Carrascon,
  • Víctor Cervera-Carrascon,
  • Víctor Cervera-Carrascon,
  • Annabrita Hemmes,
  • Susanna Grönberg-Vähä-Koskela,
  • Susanna Grönberg-Vähä-Koskela,
  • Susanna Grönberg-Vähä-Koskela,
  • João Manuel Santos,
  • João Manuel Santos,
  • João Manuel Santos,
  • Dafne C. A. Quixabeira,
  • Dafne C. A. Quixabeira,
  • Dafne C. A. Quixabeira,
  • Saru Basnet,
  • Saru Basnet,
  • Camilla Heiniö,
  • Camilla Heiniö,
  • Victor Arias,
  • Victor Arias,
  • Elise Jirovec,
  • Elise Jirovec,
  • Shreyas Kaptan,
  • Riikka Havunen,
  • Riikka Havunen,
  • Riikka Havunen,
  • Suvi Sorsa,
  • Suvi Sorsa,
  • Suvi Sorsa,
  • Abdullah Erikat,
  • Joel Schwartz,
  • Marjukka Anttila,
  • Katri Aro,
  • Katri Aro,
  • Tapani Viitala,
  • Ilpo Vattulainen,
  • Vincenzo Cerullo,
  • Vincenzo Cerullo,
  • Anna Kanerva,
  • Akseli Hemminki,
  • Akseli Hemminki,
  • Akseli Hemminki,
  • Akseli Hemminki

DOI
https://doi.org/10.3389/fimmu.2023.1060540
Journal volume & issue
Vol. 14

Abstract

Read online

IntroductionImmune checkpoint inhibitors (ICIs) have revolutionized the treatment of cancer, but preclinical testing of hypotheses such as combination therapies has been complicated, in part due to species incompatibility issues. For example, one of few known permissive animal models for oncolytic adenoviruses is the Syrian hamster, for which an ICI, mainly an anti-PD-L1 monoclonal antibody (mAb) was not previously available. In this study, we developed an anti-Syrian hamster PD-L1 mAb to enable the evaluation of safety and efficacy, when combining anti-PD-L1 with an oncolytic adenovirus encoding tumour necrosis factor alpha (TNFα) and interleukin-2 (IL-2) (Ad5/3-E2F-D24-hTNFα-IRES-hIL-2 or TILT-123).MethodsRecombinant Syrian hamster PD-L1 was expressed and mice immunized for mAb formation using hybridoma technology. Clonal selection through binding and functional studies in vitro, in silico and in vivo identified anti-PD-L1 clone 11B12-1 as the primary mAb candidate for immunotherapy modelling. The oncolytic virus (OV) and ICI combination approach was then evaluated using 11B12-1 and TILT-123 in a Syrian hamster model of pancreatic ductal adenocarcinoma (PDAC).ResultsSupernatants from hybridoma parent subclone 11B12B4 provided the highest positive PD-L1 signal, on Syrian hamster PBMCs and three cancer cell lines (HT100, HapT1 and HCPC1). In vitro co-cultures revealed superior immune modulated profiles of cell line matched HT100 tumour infiltrating lymphocytes when using subclones of 7G2, 11B12 and 12F1. Epitope binning and epitope prediction using AlphaFold2 and ColabFold revealed two distinct functional epitopes for clone 11B12-1 and 12F1-1. Treatment of Syrian hamsters bearing HapT1 tumours, with 11B12-1 induced significantly better (p<0.05) tumour growth control than isotype control by day 12. 12F1-1 did not induce significant tumour growth control. The combination of 11B12-1 with oncolytic adenovirus TILT-123 improved tumour growth control further, when compared to monotherapy (p<0.05) by day 26.ConclusionsNovel Syrian hamster anti-PD-L1 clone 11B12-1 induces tumour growth control in a hamster model of PDAC. Combining 11B12-1 with oncolytic adenovirus TILT-123 improves tumour growth control further and demonstrates good safety and toxicity profiles.

Keywords